| Drug General Information |
| Drug ID |
D04ODF
|
| Drug Name |
LY-3390334
|
| Synonyms |
LY-3390334; 206444-72-6; LY-3390334; LY-339840; LY-367366; LY-393053
|
| Indication |
Unspecified
|
Investigative |
[1]
|
|---|
| Target and Pathway |
| Target(s) |
Metabotropicglutamate receptor 1 |
Target Info |
Modulator |
|
|---|
| Metabotropic glutamate receptor 5 |
Target Info |
Modulator |
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
FoxO signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Long-term potentiation
|
|
Retrograde endocannabinoid signaling
|
|
Glutamatergic synapse
|
|
Long-term depression
|
|
Estrogen signaling pathwayhsa04020:Calcium signaling pathway
|
|
Huntington's disease
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Metabotropic glutamate receptor group III pathway
|
|
Metabotropic glutamate receptor group I pathway
|
|
Endogenous cannabinoid signalingP00027:Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Endogenous cannabinoid signaling
|
|
Reactome
|
G alpha (q) signalling events
|
|
Class C/3 (Metabotropic glutamate/pheromone receptors)R-HSA-416476:G alpha (q) signalling events
|
|
Class C/3 (Metabotropic glutamate/pheromone receptors)
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
GPCRs, Class C Metabotropic glutamate, pheromone
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
| References |
| REF 1 | Inhibition of group I metabotropic glutamate receptor responses in vivo in rats by a new generation of carboxyphenylglycine-like amino acid antagonists. |
|---|
